Edition:
United States

Profile: Corcept Therapeutics Inc (CORT.PH)

CORT.PH on Philadelphia Stock Exchange

10.89USD
17 May 2019
Change (% chg)

$0.03 (+0.28%)
Prev Close
$10.86
Open
$10.95
Day's High
$10.98
Day's Low
$10.81
Volume
649
Avg. Vol
3,923
52-wk High
$19.91
52-wk Low
$9.51

Corcept Therapeutics Incorporated, incorporated on May 13, 1998, is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, the Company also had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. The Company is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

The Company has received approval from the United States Food and Drug Administration (FDA) for Korlym (mifepristone) 300 milligrams (mg) Tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome who have type II diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is enrolling patients in a Phase II trial of its selective cortisol modulator, CORT125134, to treat patients with Cushing syndrome. It is developing a CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at GR. It is conducting a Phase I/II trial of Abraxane (nab-paclitaxel) in combination with CORT125134 to treat any solid-tumor cancer suitable for treatment with Abraxane.

The Company competes with Novartis, Laboratoire HRA Pharma, Strongbridge Biopharma plc and Medi Challenge (Pty) Ltd.

Company Address

Corcept Therapeutics Inc

149 Commonwealth Dr
MENLO PARK   CA   94025-1133
P: +1650.3273270
F: +1650.3273218

Company Web Links